Table 5_Road transportation is associated with decreased intestinal motility in horses.docx by Sharanne L. Raidal (3097719)

“…Signalment and past travel history were not predictive of intestinal motility, but horses with unknown or no prior travel history (mean 12.8, 95%CI 8.2-17.4 nmol/L) had higher cortisol concentrations prior to departure than horses known to have travelled previously (7.9, 5.8−9.9 nmol/L, p = 0.023).…”

Word cloud with key elements of an Active Learning Classroom. by Mairena Sánchez-López (684092)

Point cloud fusion instance effect. by Hongliang Zou (20707270)

Subjects:

CM-DWM-EC chart using 30% decrease in the mean for the E(KeV). by Shumaila Nisar (20114256)

“…<p>CM-DWM-EC chart using 30% decrease in the mean for the E(KeV).</p>…”

ANN architecture. by Abdelfattah Dani (22226715)

HSP90 inhibition by RGRN-305 decreased the gene expression of proinflammatory cytokines induced by SARS-CoV-2 S protein. by Hakim Ben Abdallah (14578241)

ANN architecture and configuration. by Abdelfattah Dani (22226715)

Table 3_Road transportation is associated with decreased intestinal motility in horses.docx by Sharanne L. Raidal (3097719)

“…Signalment and past travel history were not predictive of intestinal motility, but horses with unknown or no prior travel history (mean 12.8, 95%CI 8.2-17.4 nmol/L) had higher cortisol concentrations prior to departure than horses known to have travelled previously (7.9, 5.8−9.9 nmol/L, p = 0.023).…”

Table 2_Road transportation is associated with decreased intestinal motility in horses.docx by Sharanne L. Raidal (3097719)

“…Signalment and past travel history were not predictive of intestinal motility, but horses with unknown or no prior travel history (mean 12.8, 95%CI 8.2-17.4 nmol/L) had higher cortisol concentrations prior to departure than horses known to have travelled previously (7.9, 5.8−9.9 nmol/L, p = 0.023).…”

Table 6_Road transportation is associated with decreased intestinal motility in horses.docx by Sharanne L. Raidal (3097719)

“…Signalment and past travel history were not predictive of intestinal motility, but horses with unknown or no prior travel history (mean 12.8, 95%CI 8.2-17.4 nmol/L) had higher cortisol concentrations prior to departure than horses known to have travelled previously (7.9, 5.8−9.9 nmol/L, p = 0.023).…”

Table 7_Road transportation is associated with decreased intestinal motility in horses.xlsx by Sharanne L. Raidal (3097719)

“…Signalment and past travel history were not predictive of intestinal motility, but horses with unknown or no prior travel history (mean 12.8, 95%CI 8.2-17.4 nmol/L) had higher cortisol concentrations prior to departure than horses known to have travelled previously (7.9, 5.8−9.9 nmol/L, p = 0.023).…”

Table 1_Road transportation is associated with decreased intestinal motility in horses.docx by Sharanne L. Raidal (3097719)

“…Signalment and past travel history were not predictive of intestinal motility, but horses with unknown or no prior travel history (mean 12.8, 95%CI 8.2-17.4 nmol/L) had higher cortisol concentrations prior to departure than horses known to have travelled previously (7.9, 5.8−9.9 nmol/L, p = 0.023).…”

Table 4_Road transportation is associated with decreased intestinal motility in horses.docx by Sharanne L. Raidal (3097719)

“…Signalment and past travel history were not predictive of intestinal motility, but horses with unknown or no prior travel history (mean 12.8, 95%CI 8.2-17.4 nmol/L) had higher cortisol concentrations prior to departure than horses known to have travelled previously (7.9, 5.8−9.9 nmol/L, p = 0.023).…”

Baseline patient characteristics across neutralizing monoclonal antibody trials. by Elizabeth S. Munroe (21568166)

Subjects:

Quantitative antibody and antigen responses to nMAb vs placebo day 1-90: Pooled analysis of neutralizing monoclonal antibodies. by Elizabeth S. Munroe (21568166)

Subjects:

Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for neutralizing monoclonal antibodies, among patients alive and with day 90 antibody and antigen measu... by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Amubarvimab/ Romlusevimab. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to Ensovibep vs placebo day 1–90. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Tixagevimab/ Cilgavimab. by Elizabeth S. Munroe (21568166)

Subjects:

Study Flow Diagram. by Elizabeth S. Munroe (21568166)

Subjects: